Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, 280 Mohe Road, Shanghai, 201999, China.
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Mol Cancer. 2017 Oct 11;16(1):157. doi: 10.1186/s12943-017-0724-6.
MicroRNAs (miRNAs) are important regulators involved in diverse physiological and pathological processes including cancer. SUMO (small ubiquitin-like modifier) is a reversible protein modifier. We recently found that SUMOylation of TARBP2 and DGCR8 is involved in the regulation of the miRNA pathway. KHSRP is a single stranded nucleic acid binding protein with roles in transcription and mRNA decay, and it is also a component of the Drosha-DGCR8 complex promoting the miRNA biogenesis.
The in vivo SUMOylation assay using the Ni-NTA affinity pulldown or immunoprecipitation (IP) and the in vitro E.coli-based SUMOylation assay were used to analyze SUMOylation of KHSRP. Nuclear/Cytosol fractionation assay and immunofluorescent staining were used to observe the localization of KHSRP. High-throughput miRNA sequencing, quantantive RT-PCR and RNA immunoprecipitation assay (RIP) were employed to determine the effects of KHSRP SUMO1 modification on the miRNA biogenesis. The soft-agar colony formation, migration, vasculogenic mimicry (VM) and three-dimensional (3D) cell culture assays were performed to detect the phenotypes of tumor cells in vitro, and the xenograft tumor model in mice was conducted to verify that SUMO1 modification of KHSRP regulated tumorigenesis in vivo.
KHSRP is modified by SUMO1 at the major site K87, and this modification can be increased upon the microenvironmental hypoxia while reduced by the treatment with growth factors. SUMO1 modification of KHSRP inhibits its interaction with the pri-miRNA/Drosha-DGCR8 complex and probably increases its translocation from the nucleus to the cytoplasm. Consequently, SUMO1 modification of KHSRP impairs the processing step of pre-miRNAs from pri-miRNAs which especially harbor short G-rich stretches in their terminal loops (TL), resulting in the downregulation of a subset of TL-G-Rich miRNAs such as let-7 family and consequential tumorigenesis.
Our data demonstrate how the miRNA biogenesis pathway is connected to tumorigenesis and cancer progression through the reversible SUMO1 modification of KHSRP.
MicroRNAs (miRNAs) 是参与多种生理和病理过程的重要调节因子,包括癌症。SUMO(小泛素样修饰物)是一种可逆的蛋白质修饰物。我们最近发现 TARBP2 和 DGCR8 的 SUMOylation 参与了 miRNA 通路的调节。KHSRP 是一种单链核酸结合蛋白,在转录和 mRNA 降解中发挥作用,也是促进 miRNA 生物发生的 Drosha-DGCR8 复合物的组成部分。
使用 Ni-NTA 亲和下拉或免疫沉淀 (IP) 进行体内 SUMOylation 测定,以及基于大肠杆菌的体外 SUMOylation 测定分析 KHSRP 的 SUMOylation。核/胞浆分离测定和免疫荧光染色用于观察 KHSRP 的定位。高通量 miRNA 测序、定量 RT-PCR 和 RNA 免疫沉淀测定 (RIP) 用于确定 KHSRP SUMO1 修饰对 miRNA 生物发生的影响。软琼脂集落形成、迁移、血管生成模拟 (VM) 和三维 (3D) 细胞培养测定用于检测体外肿瘤细胞的表型,以及在小鼠中进行异种移植肿瘤模型以验证 KHSRP SUMO1 修饰调节体内肿瘤发生。
KHSRP 在主要位点 K87 处被 SUMO1 修饰,这种修饰可以在微环境缺氧时增加,而在生长因子处理时减少。KHSRP 的 SUMO1 修饰抑制其与 pri-miRNA/Drosha-DGCR8 复合物的相互作用,并可能增加其从核到细胞质的易位。因此,KHSRP 的 SUMO1 修饰会损害 pri-miRNA 加工步骤,特别是在其末端环 (TL) 中含有短 G 丰富区的 pre-miRNAs,导致 let-7 家族等短 G 丰富 miRNA 的下调,从而导致肿瘤发生。
我们的数据表明,miRNA 生物发生途径如何通过 KHSRP 的可逆 SUMO1 修饰与肿瘤发生和癌症进展相关。